Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma…
1D
-0.4%
1W
-1.5%
1M
-15.3%
6M
-35.9%
YTD
-27.1%
1Y
-18.0%
2Y
+107.3%
5Y
-80.6%
10Y
–
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~135% stronger price swings than usual
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.50
MEDIAN
US$6.50
PRICE TARGET HIGH
US$7.00
0
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 11/03/2026
P/E
-12.34
P/B
10.08
EV/EBITDA
-74.41
RETURN ON EQUITY
-30.4%
NET MARGIN
-23.4%
DEBT/EQUITY
3.72
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
86.4%
FLOAT SHARES
36,411,059
AVG. DAILY VOLUME (30D)
139,366
Waldman Lawrence
Waldman Lawrence
Roman Shawn David
Roman Shawn David
Vizirgianakis Stavros G.
Apyx Medical Corporation is a company in the Healthcare sector, Medical - Specialties industry, headquartered in United States.
The CEO is Charles D. Goodwin, the company employs around 205 people.
The IPO was on 02/01/2019; the stock trades on NASDAQ under the ticker APYX.
9 analysts rate the stock, the consensus is Buy (as of 11/03/2026).
The average price target is US$6.50, ranging from US$6.00 to US$7.00, with a median of US$6.50.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 135% stronger than usual.
No, Apyx Medical currently does not pay a dividend.
Comparable stocks include STERIS, QuidelOrtho, Mesa Laboratories, 908 Devices, Trinity Biotech, Eli Lilly and Company, Johnson & Johnson and AbbVie.
Clicking "Analyze stock" lets five strategies assess Apyx Medical against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.